Drug intelligence / Profile preview

SCG-452

Development stage: Preclinical
Lead developer: SCG Cell Therapy
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

SCG-452 is an investigational cell therapy product based on induced pluripotent stem cells (iPSC). It is being developed by SCG Cell Therapy for the treatment of neoplasms, specifically solid tumors. The drug is currently in preclinical development and has not yet entered clinical trials. Detailed information about its mechanism of action, specific cellular engineering, or target antigens has not been disclosed publicly as of June 2025[1][2][3][7].

Beyond the preview

Go deeper on SCG-452.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCG-452.

Explore the full profile